- Satellos Bioscience (MSCL) has created, prioritized and advanced novel small-molecule drug candidates into further preclinical studies
- The compounds are strong and selective inhibitors of a particular kinase protein in the Notch pathway
- The plan is to evaluate and prioritize these compounds for ADME, pharmacokinetics and in vivo efficacy
- Satellos is a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle conditions
- Satellos Bioscience (MSCL) is up under 2 per cent, trading at C$0.26 AT 10:38 am EST
Satellos Bioscience (MSCL) has created, prioritized and advanced novel small-molecule drug candidates into further preclinical studies.
The company’s compounds are strong and selective inhibitors of a particular kinase protein in the Notch pathway, which the company is calling K9 for confidentiality reasons.
Satellos’ scientists have discovered that inhibiting this target enables the modulation of the muscle stem cell division and regeneration process in its lead disease indication, Duchenne muscular dystrophy.
The company plans to evaluate and prioritize these compounds for absorption, distribution, metabolism and excretion (ADME), pharmacokinetics (PK) and in vivo efficacy.
While the end goal is to finalize these studies and have them analyzed by the end of 2022, in doing so, the company hopes it will be able to choose prospective lead and backup drug candidates for IND-enabling drug development studies.
“The K9 drug target is quite well understood pharmaceutically, in a completely unrelated therapeutic area to Duchenne where it has been independently studied in both phase 1 and phase 2 clinical studies,” said Frank Gleeson, President and CEO of Satellos.
“The fact that this target has been assessed in another setting without apparent signs of obvious safety concerns is encouraging to us as this may help de-risk our program,” continued Gleeson.
“This is an important step as we move towards the clinic with small molecule therapeutics to regenerate muscle in patients with muscle loss,” said Phil Lambert, Ph.D., Chief Technology Officer at Satellos.
“Now, we are undertaking studies to prioritize and advance one or more molecules with the appropriate PK in muscle to mimic the effect on the muscle regeneration process that we have already seen with tool compounds,” concluded Lambert.
Satellos is a biotechnology company that develops life-changing medicines to treat degenerative muscle conditions.
Scientists from the company found a previous root cause of skeletal muscle degeneration. The company is excited about this because they believe they have the potential to transform how muscle disorders are treated.
Satellos Bioscience (MSCL) is up under 2 per cent, trading at C$0.26 AT 10:38 am EST.